UK biotech Exscientia has tapped the brakes on the rapid expansion of its R&D pipeline, narrowing its in-house activities to oncology programmes that it says offer the greatest chance of making a difference to patients.The specialist in applying artificial intelligence to drug discovery is zeroing in on its CDK7 and LSD1 programmes, currently at or […]
